Principal Financial Group’s Legend Biotech LEGN Stock Holding History

Principal Financial Group’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.03M	Buy	+104,994	New	+$2.83M	﹤0.01%	1782

Other funds holding LEGN

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

IAMH

IvyRock Asset Management (HK) Sheung Wan, Hong Kong $177M AUM 10.49% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

ELI

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

IGAM

iA Global Asset Management Quebec, Quebec, Canada $8.42B AUM 47.61% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group's LEGN Position: Q2 2026 in Review

Principal Financial Group opened a new position in Legend Biotech (LEGN) in Q2 2026: 104,994 shares worth $3.03M. The stake represents ﹤0.01% of the portfolio and ranks #1782 among its holdings.

66 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

Principal Financial Group held 104,994 shares of Legend Biotech worth $3.03M as of Q2 2026.
Legend Biotech was a new Principal Financial Group position in Q2 2026.
Legend Biotech made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #1782 holding.
66 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.